Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
作者信息
Murrell Dédée F, Joly Pascal, Werth Victoria P, Ujiie Hideyuki, Worm Margitta, Mangold Aaron R, Avetisova Elena, Maloney Jennifer, Laws Elizabeth, Mortensen Eric, Dubost-Brama Ariane, Shabbir Arsalan
机构信息
Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia.
The Church, 17 Kensington St, Kogarah, NSW, 2217, Australia.
出版信息
Adv Ther. 2024 Jul;41(7):3014-3015. doi: 10.1007/s12325-024-02886-x.
Abstract
摘要
相似文献
1
Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.对《度普利尤单抗治疗大疱性类天疱疮成人患者的2/3期随机对照试验：LIBERTY-BP ADEPT的研究设计》的勘误
Adv Ther. 2024 Jul;41(7):3014-3015. doi: 10.1007/s12325-024-02886-x.
2
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.研究设计：一项评估度普利尤单抗治疗大疱性类天疱疮成人患者的 2/3 期随机对照试验：LIBERTY-BP ADEPT。
Adv Ther. 2024 Jul;41(7):2991-3002. doi: 10.1007/s12325-024-02810-3. Epub 2024 Mar 5.
3
Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.度普利尤单抗治疗大疱性类天疱疮有效性和安全性的真实世界评估：一项前瞻性队列多中心病例系列研究
Br J Dermatol. 2025 Feb 18;192(3):501-509. doi: 10.1093/bjd/ljae403.
4
Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study.度普利尤单抗治疗大疱性类天疱疮期间快速止痒可预测临床疗效：一项回顾性队列研究
Dermatology. 2024;240(5-6):694-701. doi: 10.1159/000540590. Epub 2024 Jul 29.
5
Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.度普利尤单抗治疗严重大疱性类天疱疮的长期疗效和安全性：一项前瞻性队列研究。
Int Immunopharmacol. 2023 Dec;125(Pt A):111157. doi: 10.1016/j.intimp.2023.111157. Epub 2023 Nov 3.
6
Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study.度普利尤单抗和奥马珠单抗治疗大疱性类天疱疮的有效性：一项全国性回顾性队列研究。
J Dermatol. 2025 Jun;52(6):983-1000. doi: 10.1111/1346-8138.17742. Epub 2025 Apr 16.
7
Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.度普利尤单抗联合低剂量全身类固醇治疗改善大疱性类天疱疮的疗效和安全性。
Dermatol Ther. 2022 Aug;35(8):e15648. doi: 10.1111/dth.15648. Epub 2022 Jul 1.
8
Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid.度普利尤单抗、皮质类固醇及其联合用药治疗大疱性类天疱疮
An Bras Dermatol. 2025 Mar-Apr;100(2):243-252. doi: 10.1016/j.abd.2024.04.012. Epub 2024 Dec 17.
9
Evaluation of Dupilumab in Patients With Bullous Pemphigoid.评价度普利尤单抗治疗大疱性类天疱疮的疗效。
JAMA Dermatol. 2023 Sep 1;159(9):953-960. doi: 10.1001/jamadermatol.2023.2428.
10
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?度普利尤单抗在大疱性类天疱疮中的应用：我们目前的进展如何？
J Clin Med. 2022 Jun 12;11(12):3367. doi: 10.3390/jcm11123367.
引用本文的文献
1
JAK-STAT pathway, type I/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid.JAK-STAT信号通路、I/II型细胞因子与自身免疫性大疱性疾病的新潜在治疗策略：寻常型天疱疮和大疱性类天疱疮的最新进展
Front Immunol. 2025 Apr 8;16:1563286. doi: 10.3389/fimmu.2025.1563286. eCollection 2025.
Zotero 插件